Loading…
← CockpitCompetitor Analysis › 2105.HK Laekna, Inc.Open in the cockpit ↗

Laekna, Inc.2105.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Biotechnology
Momentum weak 38
Mkt cap
$326M
US dollars, full cap
Free float
57%
of shares outstanding
$/day
$955,523
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-82.7 pp
WACC 10.5%
Hurdle
n/a
no reverse DCF
Next earnings
132 days
30 Mar 2027
Close · HKDHK$6.22
1D-5.8%
1W-5.7%
1M-1.2%
3M-0.9%
6M-52.8%
YTD-54.1%
1Y-41.0%
ATR %7.7%
52w lowhigh67.8% off high

What Laekna does

Employees: 83

Laekna at a glance

Size Laekna (2105.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $326M, the 862nd largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$6.22 on 18 Nov 2026.

Performance Over six months the shares fell 52.8%, against -24.7% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 2nd lowest of 20 in its peer set.

Growth The operating margin is -56.9% (peer median -244.5%).

Valuation It trades at 4.7× enterprise value to sales against a peer median of 7.5× (6th cheapest of 15).

Capital Return on invested capital runs 82.7 points below its cost of capital (10.5% WACC).

Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).

Relative performance

40608010021 May 202621 Aug 202618 Nov 2026Peer median 702105.HK 48
Six months, rebased to 100: Laekna against the median of its 20 peers (local-currency closes).

Laekna financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$288MHK$116MHK$0HK$0HK$0
Revenue growth—————
Gross profitHK$235MHK$87.8M-HK$5.58M-HK$5.78M-HK$7.66M
EBITDA-HK$156M-HK$287M-HK$308M-HK$318M-HK$422M
Net income-HK$112M-HK$249M-HK$276M-HK$408M-HK$909M
Free cash flow-HK$96.9M-HK$67.3M-HK$269M-HK$314M-HK$359M
Capital expenditureHK$1.08MHK$1.15MHK$2.07MHK$1.45MHK$5.91M
Total debtn/aHK$135MHK$111MHK$62.1MHK$2.59B

Quarterly statements and history in the cockpit →

Laekna competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%-25%0%+25%CCCC694538807630PROKLRMR358570LYELNAUT4894086900GLSIGALTCRMDCTNM4760602105.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Laekna is the large dot.

Laekna competitors and peer comparison

How Laekna compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Laekna against its 20 peers (data as of 18 Nov 2026)
Measure2105.HKPeer medianRank in peer set
1-month return-1.2%-5.7%5th highest of 20
6-month return-52.8%-24.7%2nd lowest of 20
Distance from 52-week high-67.8%-52.1%3rd lowest of 20
Operating margin-56.9%-244.5%7th highest of 15
EV / Sales4.7×7.5×6th cheapest of 15
ROIC minus cost of capital-82.7 pp-22.1 pp5th lowest of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Laekna 2105.HKHong Kong$326M-53%n/a-57%4.7×n/an/a
C4 Therapeutics CCCCUnited States$325M-25%+7%-316%5.4×n/an/a
AP Biosciences 6945.TWOTaiwan$321M-31%n/an/an/an/an/a
Medtide 3880.HKHong Kong$331M-17%+14%36%2.4×n/an/a
IMPACT Therapeutics 7630.HKHong Kong$319M-79%+395%-173%9.5×n/an/a
ProKidney PROKUnited States$314M-38%+4%-24,830%1,625.4×n/an/a
Larimar Therapeutics LRMRUnited States$337M-9%n/an/an/an/an/a
GI Innovation 358570.KSSouth Korea$339M-47%+1,527%-918%78.5×n/an/a
Lyell Immunopharma LYELUnited States$341M-19%-63%-1,388,360%13,911.5×n/an/a
Nautilus Biotechnolgy NAUTUnited States$310M+2%n/a-15,106%588.9×n/an/a
Cuorips 4894.TJapan$309M-10%-80%-1,765%602.9×n/an/a
X4 Pharmaceuticals XFORUnited States$304M-21%-50%-474%11.4×n/an/a
Aspen Neuroscience ASPEUnited States$349Mn/an/an/an/an/an/a
Viva Biotech 1873.HKHong Kong$303M-18%+7%10%1.0×2.6%+19.1%
Medy-Tox 086900.KSSouth Korea$350M-36%+3%10%2.2×4.7%+11.9%
Greenwich LifeSciences GLSIUnited States$302M-25%n/an/an/an/an/a
Galectin Therapeutics GALTUnited States$301M+35%n/an/an/an/an/a
CorMedix CRMDUnited States$358M-43%+92%39%0.4×n/an/a
Contineum Therapeutics CTNMUnited States$363M-31%n/an/an/an/an/a
Onconic Therapeutics 476060.KSSouth Korea$368M-49%+179%21%5.2×0.6%+725.2%
Guangdong Vtr Bio-Tech 300381.SZChina$370M-31%0%-4%2.6×n/an/a

Questions

Which companies are Laekna's closest peers?
The cockpit's peer set: C4 Therapeutics (CCCC), AP Biosciences (6945.TWO), Medtide (3880.HK), IMPACT Therapeutics (7630.HK), ProKidney (PROK), Larimar Therapeutics (LRMR), GI Innovation (358570.KS), Lyell Immunopharma (LYEL).
Is Laekna expensive compared with its peers?
On ev / sales it trades at 4.7× against a peer median of 7.5×, 6th cheapest of 15 in its peer set.
How has Laekna stock performed?
Over six months to 18 Nov 2026 the shares returned -52.8% against -24.7% for the median peer; over one year -41.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.